Erratum To “diagnosis And Treatment Of Chronic Lymphocytic Leukemia: Recommendations From The Brazilian Group Of Chronic Lymphocytic Leukemia”

dc.creatorRodrigues C.A.
dc.creatorGonçalves M.V.
dc.creatorIkoma M.R.V.
dc.creatorLorand-Metze I.
dc.creatorPereira A.D.
dc.creatorFarias D.L.C.D.
dc.creatorChauffaille M.D.L.L.F.
dc.creatorSchaffel R.
dc.creatorRibeiro E.F.O.
dc.creatorRocha T.S.D.
dc.creatorBuccheri V.
dc.creatorVasconcelos Y.
dc.creatorFigueiredo V.L.D.P.
dc.creatorChiattone C.S.
dc.creatorYamamoto M.
dc.date2017
dc.date2017-08-17T19:10:17Z
dc.date2017-08-17T19:10:17Z
dc.date.accessioned2018-03-29T05:15:12Z
dc.date.available2018-03-29T05:15:12Z
dc.identifierRevista Brasileira De Hematologia E Hemoterapia. Elsevier Editora Ltda, v. 39, n. 1, p. 93 - 94, 2017.
dc.identifier1516-8484
dc.identifier10.1016/j.bjhh.2017.01.002
dc.identifierhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85014292558&doi=10.1016%2fj.bjhh.2017.01.002&partnerID=40&md5=7b7142665aae46147ac86d8d5373312b
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/322996
dc.identifier2-s2.0-85014292558
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1357159
dc.descriptionIn the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction: 2) Relapsed first-line treatment: a) Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)b) Progress within 24 months: - ‘Go-go’ patients: ibrutinib • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab- ‘Slow-go’ patients: ibrutinib • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
dc.description39
dc.description1
dc.description93
dc.description94
dc.languageEnglish
dc.publisherElsevier Editora Ltda
dc.relationRevista Brasileira de Hematologia e Hemoterapia
dc.rightsaberto
dc.sourceScopus
dc.titleErratum To “diagnosis And Treatment Of Chronic Lymphocytic Leukemia: Recommendations From The Brazilian Group Of Chronic Lymphocytic Leukemia”
dc.typeErrata


Este ítem pertenece a la siguiente institución